Abstract: A system for the assessment and treatment of the cervical spine is provided.

Abstract: A composition comprising nanoparticles, a method for the preparation of a composition comprising nanoparticles and uses of the composition for dental treatment are provided. Each nanoparticle is made of polymeric material and includes an antimicrobial agent encapsulated therein. The polymeric material can include Poly(lactic-co-glycolic acid) (PLGA), or other polymers such as Polylactic (PLA), Polyglycolic (PGA), or Polycaprolactone (PCL). The active molecule is calcium hydroxide in the range of 0.1 to 5 mg/ml. The composition has a pH in the range of 8-13.

Abstract: Systems and devices, and methods operable therein, to provide lossless broadband communications, via the Internet, between a Customer Premises Equipment (CPE) device and a Provider Edge (PE) Router associated with a Virtual Private Network.

Abstract: The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment.

Abstract: A method of treating metastases (e.g., brain metastases) in a patient with cancer (e.g., lung cancer) and at risk for metastases, exhibiting symptoms of metastases, or identified with metastases includes administering a therapeutically effective amount of a RICTOR inhibitor for the treatment of metastases. A method of reducing resistance to an EGFR, MET or AKT inhibitor in a cancer patient being administered the EGFR. MET or AKT inhibitor comprises co-administering a therapeutically effective amount of a RICTOR inhibitor and the EGFR, MET or AKT inhibitor. RICTOR inhibitors include compounds of formulas I-IV.

Abstract: The present invention relates to a preparation method for core-shell structured fibrous scaffolds, and more specifically to preparing a core part composition and a shell part composition that each have different constitutions by adding calcium phosphate cement and a protein, drug of combination thereof to alginate solution, and then inserting the above core part composition and shell part composition to internal and external nozzle of concentric nozzle respectively to inject into calcium ion aqueous solution and thereby hardening them, thus preparing core-shell structured rapidly setting Alg/?-TCP scaffolds capable of controllably releasing a protein or drug.

Abstract: The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25?-dihydroxyvitamin D3 (1,25D), with the advantage of producing less or no hypercalcemia.

Abstract: The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25?-dihydroxyvitamin D3 (1,25D), with the advantage of producing less or no hypercalcemia.

Abstract: One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml. Another aspect of the invention relates to lipid-complexed platinum compound compositions where the concentration of the platinum compound is greater than about 1.2 mg/ml.

Abstract: The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment.

Abstract: One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml. Another aspect of the invention relates to lipid-complexed platinum compound compositions where the concentration of the platinum compound is greater than about 1.2 mg/ml.

Abstract: The present invention relates to a preparation method for core-shell structured fibrous scaffolds, and more specifically to preparing a core part composition and a shell part composition that each have different constitutions by adding calcium phosphate cement and a protein, drug of combination thereof to alginate solution, and then inserting the above core part composition and shell part composition to internal and external nozzle of concentric nozzle respectively to inject into calcium ion aqueous solution and thereby hardening them, thus preparing core-shell structured rapidly setting Alg/?-TCP scaffolds capable of controllably releasing a protein or drug.

Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Abstract: Cosmetic or dermopharmaceutical compositions containing Pseudoalteromonas ferment extract for the treatment and/or care of the skin, scalp and/or nails, preferably to improve the barrier function of the skin, scalp and/or nails, and specifically for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, scalp and/or nails associated with an alteration in the keratinization process.

Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Abstract: The present invention relates to combinations of PM02734 with EGFR tyrosine kinase inhibitors, and the use of these combinations in the treatment of cancer.

Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.

Abstract: The present invention is directed to methods for treating bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to methods for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for treating bronchial premalignancy and/or lung cancer in a subject comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier.

Abstract: The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.